Place in therapy of olmesartan
Qual è il Giusto Place in Therapy Dell'olmesartan?
DOI:
https://doi.org/10.33393/grhta.2017.388Keywords:
Angiotensin receptor blockers, Drug expenditure, Drug utilization, Olmesartan, Place in therapy, Post-marketing safetyAbstract
Olmesartan has been de-reimbursed in France since January 2017 following a negative evaluation of its benefit/risk profile compared with other sartans. However, olmesartan is one of the antihypertensive blockbusters in Italy in terms of usage and expenditure. This article illustrates the pathway leading to a critical appraisal issued by the Lazio Regional Committee for Medicines with the aim of promoting the rational use of olmesartan and its place in therapy. Moreover, this short communication offers potential scenarios to combine the use of evidence-based information about a widely prescribed antihypertensive drug with cost considerations related to the entire class of sartans.Downloads
Download data is not yet available.
Downloads
Published
2017-06-16
How to Cite
Addis, A., & Trotta, F. (2017). Place in therapy of olmesartan: Qual è il Giusto Place in Therapy Dell’olmesartan?. Global and Regional Health Technology Assessment, 4(1), 141–144. https://doi.org/10.33393/grhta.2017.388
Issue
Section
Point of View
License
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
